Noreen N, Muhammad F, Akhtar B, Azam F, Anwar MI. Is Cannabidiol a promising substance for new drug development? A review of its potential therapeutic applications. Crit Rev Eukaryot Gene Expr. 2018;28:73–86.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, Group GS. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2018;391:1085–96.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S. Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM. Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–97.
U.S. Food and Drug Administration Center for Drug Evaluation and Research. Epidiolex NDA 210365 Approval Letter. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000Approv.pdf. 30th March 2021.
Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimaraes FS, Crippa JA. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019;41:9–14.
Zuardi AW, Crippa JAS, Hallak JEC, Gorayeb R. Human experimental anxiety: actual public speaking induces more intense physiological responses than simulated public speaking. Rev Bras Psiquiatr. 2013;35:248–53.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175:225–31.
Millar SA, Stone NL, Yates AS, Sullivan SE. A systematic review on the pharmacokinetics of Cannabidiol in humans. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01365.
Larsen C, Shahinas J. Dosage, efficacy and safety of Cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res. 2020;12:129–41.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified Cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053–67.
Arnold JC, Nation T, McGregor IS. Prescribing medicinal cannabis. Aust Prescr. 2020;43:152–9.
Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30:271–80.
Leas EC, Nobles AL, Caputi TL, Dredze M, Smith DM, Ayers JW. Trends in Internet searches for Cannabidiol (CBD) in the United States. JAMA Netw Open. 2019;2:e1913853.
Kasper AM, Sparks SA, Hooks M, Skeer M, Webb B, Nia H, Morton JP, Close GL. High prevalence of Cannabidiol use within male professional Rugby Union and League Players: a quest for pain relief and enhanced recovery. Int J Sport Nutr Exerc Metab. 2020;30:1–8.
McGregor IS, Cairns EA, Abelev S, Cohen R, Henderson M, Couch D, Arnold JC, Gauld N. Access to cannabidiol without a prescription: a cross-country comparison and analysis. Int J Drug Policy. 2020;85:102935.
World Anti Doping Agency. Summary of major modifications and explanatory notes. 2018. https://www.wada-ama.org/sites/default/files/prohibited_list_2018_summary_of_modifications_en.pdf. 30 March 2021.
Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The effects of Cannabidiol oil on noninvasive measures of muscle damage in men. Med Sci Sports Exerc. 2021;53:1460–772.
Isenmann E, Veit S, Starke L, Flenker U, Diel P. Effects of Cannabidiol supplementation on skeletal muscle regeneration after intensive resistance training. Nutrients. 2021;13:3028.
McCartney D, Benson MJ, Desbrow B, Irwin C, Suraev A, McGregor IS. Cannabidiol and sports performance: a narrative review of relevant evidence and recommendations for future research. Sports Med Open. 2020;6:27.
Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of Cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699–730.
Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014;14:41.
Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60:1586–92.
Lakens D. Sample size justification. PsyArXiv. 2021.
Armstrong LE, Pumerantz AC, Fiala KA, Roti MW, Kavouras SA, Casa DJ, Maresh CM. Human hydration indices: acute and longitudinal reference values. Int J Sport Nutr Exerc Metab. 2010;20:145–53.
Suraev A, Grunstein RR, Marshall NS, D’Rozario AL, Gordon CJ, Bartlett DJ, Wong K, Yee BJ, Vandrey R, Irwin C, Arnold JC, McGregor IS, Hoyos CM. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open. 2020;10:e034421.
Coyle E, González-Alonso J. Cardiovascular drift during prolonged exercise: new perspectives. Exerc Sport Sci Rev. 2001;29:88–92.
Borg G. Borg’s perceived exertion and pain scales. Champaign: Human Kinetics; 1998. p. viii-104– viii.
Hardy CJ, Rejeski WJ. Not what, but how one feels: the measurement of affect during exercise. J Sport Exerc Psychol. 1989;11:304–17.
Griffin SE, Robergs RA, Heyward VH. Blood pressure measurement during exercise: a review. Med Sci Sports Exerc. 1997;29:149–59.
Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31:301–6.
Shacham S. A shortened version of the Profile of Mood States. J Pers Assess. 1983;47:305–6.
Kevin RC, Vogel R, Doohan P, Berger M, Amminger GP, McGregor IS. A validated method for the simultaneous quantification of CBD, THC, and their metabolites in human plasma, and application to plasma samples from an oral CBD open label trial. Drug Test Anal. 2020;13:614–27.
Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013. https://doi.org/10.3389/fpsyg.2013.00863.
Goulet-Pelletier JC, Cousineau D. A review of effect sizes and their confidence intervals, Part I: The Cohen’s d family. Quant Methods Psychol. 2018;14:242–65.
Borenstein MH, Higgins LV, Julian PT, Rothstein HR. Introduction to meta-analysis. West Sussex: Wiley; 2009.
Goulet-Pelletier JC, Cousineau D. Corrigendum to "A review of effect sizes and their confidence intervals, part I: the Cohen’s d family”. Quant Methods Psychol. 2018;15:54–54.
Cohen J. Statistical power analysis for the behavioural sciences. New York: Routledge; 1988.
Burke LM, Whitfield J, Heikura IA, Ross MLR, Tee N, Forbes SF, Hall R, McKay AKA, Wallett AM, Sharma AP. Adaptation to a low carbohydrate high fat diet is rapid but impairs endurance exercise metabolism and performance despite enhanced glycogen availability. J Physiol. 2020;599:771–90.
Pawlak-Chaouch M, Boissiere J, Gamelin FX, Cuvelier G, Berthoin S, Aucouturier J. Effect of dietary nitrate supplementation on metabolic rate during rest and exercise in human: a systematic review and a meta-analysis. Nitric Oxide. 2016;53:65–76.
Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exerc Physiol. 1983;55:628–34.
Nalbandian M, Radak Z, Taniguchi J, Masaki T. How different respiratory rate patterns affect cardiorespiratory variables and performance. Int J Exerc Sci. 2017;10:322–9.
Conley KE, Jubrias SA, Cress ME, Esselman P. Exercise efficiency is reduced by mitochondrial uncoupling in the elderly. Exp Physiol. 2013;98:768–77.
Conley KE, Jubrias SA, Cress ME, Esselman PC. Elevated energy coupling and aerobic capacity improves exercise performance in endurance-trained elderly subjects. Exp Physiol. 2013;98:899–907.
Hao E, Mukhopadhyay P, Cao Z, Erdelyi K, Holovac E, Liaudet L, Lee WS, Hasko G, Mechoulam R, Pacher P. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med. 2015;21:38–45.
Mukhopadhyay P, Rajesh M, Horvath B, Batkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Hasko G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50:1368–81.
Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JEC, Zuardi AW, Crippa JA, Quevedo J. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev Bras Psiquiatr. 2013;35:380–6.
da Silva VK, de Freitas BS, Dornelles VC, Kist LW, Bogo MR, Silva MC, Streck EL, Hallak JE, Zuardi AW, Crippa JAS, Schroder N. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol. Brain Res Bull. 2018;139:1–8.
Fišar Z, Singh N, Hroudová J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol Lett. 2014;231:62–71.
Rimmerman N, Ben-Hail D, Porat Z, Juknat A, Kozela E, Daniels MP, Connelly PS, Leishman E, Bradshaw HB, Shoshan-Barmatz V, Vogel Z. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4:e949.
Schultze N, Wanka H, Zwicker P, Lindequist U, Haertel B. Mitochondrial functions of THP-1 monocytes following the exposure to selected natural compounds. Toxicology. 2017;377:57–63.
Singh N, Hroudová J, Fišar Z. Cannabinoid-induced changes in the activity of electron transport chain complexes of brain mitochondria. J Mol Neurosci. 2015;56:926–31.
Wu HY, Huang CH, Lin YH, Wang CC, Jan TR. Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production. Free Radic Biol Med. 2018;124:311–8.
Richards JC, Crecelius AR, Larson DG, Dinenno FA. Acute ascorbic acid ingestion increases skeletal muscle blood flow and oxygen consumption via local vasodilation during graded handgrip exercise in older adults. Am J Physiol Heart Circ Physiol. 2015;309:H360–8.
Richards JC, Racine ML, Hearon CM, Kunkel M, Luckasen GJ, Larson DG, Allen JD, Dinenno FA. Acute ingestion of dietary nitrate increases muscle blood flow via local vasodilation during handgrip exercise in young adults. Physiol Rep. 2018;6:12.
Stanley CP, Wheal AJ, Randall MD, O’Sullivan SE. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. Eur J Pharmacol. 2013;720:376–82.
Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O’Sullivan SE. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. J Pharmacol Exp Ther. 2014;351:457–66.
Wheal AJ, Jadoon K, Randall MD, O’Sullivan SE. In vivo Cannabidiol treatment improves endothelium-dependent vasorelaxation in mesenteric arteries of Zucker diabetic fatty rats. Front Pharmacol. 2017. https://doi.org/10.3389/fphar.2017.00248.
Stanley CP, Hind WH, Tufarelli C, O’Sullivan SE. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res. 2015;107:568–78.
Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2:e93760.
Baden DA, McLean TL, Tucker R, Noakes TD, Gibson AS. Effect of anticipation during unknown or unexpected exercise duration on rating of perceived exertion, affect, and physiological function. Br J Sports Med. 2005;39:742–6.
Argueta DA, Ventura CM, Kiven S, Sagi V, Gupta K. A balanced approach for Cannabidiol use in chronic pain. Front Pharmacol. 2020. https://doi.org/10.3389/fphar.2020.00561.
Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–85.
Gyires K, Zádori ZS. Role of Cannabinoids in gastrointestinal mucosal defense and inflammation. Curr Neuropharmacol. 2016;14:935–51.
Hanlon EC. Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide). Psychoneuroendocrinology. 2020;111:104471.
Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A. Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the “runner’s high.” J Exp Biol. 2012;215:1331–6.
Raichlen DA, Foster AD, Seillier A, Giuffrida A, Gerdeman GL. Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol. 2013;113:869–75.
Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43:155–72.
Zderic TW, Coggan AR, Ruby BC. Glucose kinetics and substrate oxidation during exercise in the follicular and luteal phases. J Appl Physiol. 2001;90:447–53.